In latest months, Wall Avenue has seen a surge of healthcare companies looking for to go public, as IPO exercise continues to regain momentum after final yr’s file lows. MapLight Therapeutics, Inc. is the newest healthcare firm to leap on the IPO bandwagon, eying a $704 million valuation.
The Providing
In a latest submitting with the Securities and Alternate Fee, the corporate revealed its intention to supply 14.75 million shares in an preliminary public providing. Submit-IPO, the inventory is anticipated to commerce on the Nasdaq inventory change below the image MPLT. Morgan Stanley, Jefferies, Leerink Companions, and Stifel are the underwriters managing the providing.
The estimated IPO value is $17 per share, which interprets into internet proceeds of about $227.3 million after deducting providing bills and different prices. The corporate plans to make use of the proceeds to advance the scientific growth of its present packages, to fund analysis and growth actions for added packages, and for working capital and different common company functions.
Loss Widens
MapLight has not but generated income, because it doesn’t have any product out there. Within the six months ended June 30, 2025, the corporate incurred a lack of $52.2 million, in comparison with a loss $37.3 million within the corresponding interval final yr. Complete working bills have been $54.2 million within the first half.
MapLight is a clinical-stage biopharmaceutical firm engaged within the discovery of therapies for central nervous system issues. Christopher Kroeger, who co-founded the corporate in 2018, has served as its chief government officer, president, and member of the board of administrators since then.
Medical Packages
Presently, MapLight is conducting a phase-II trial evaluating its lead product, ML-007C-MA, for the therapy of acute schizophrenia, and expects topline ends in the second half of 2026. As well as, it’s doing an advanced-stage trial evaluating ML-007C-MA for the therapy of ADP, with topline outcomes anticipated within the second half of 2027.
